|
|
|
| Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals |
| Yan Huang, Ming-Hui Li, Min Hou and Yao Xie |
Beijing, China
Author Affiliations: Shanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China (Huang Y and Hou M); Liver Disease Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China (Li MH and Xie Y)
Corresponding Author: Yao Xie, MD, Liver Disease Center, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China (Tel: +86-10-84322284; Email: xieyao00120184@sina.com) |
|
|
|
| Guide |
|
Abstract BACKGROUND: The availability of novel direct-acting antivirals (DAAs) represents a new era of curative hepatitis C virus (HCV) treatment, with over 95% of patients infected with HCV genotype 1 achieving sustained virological response (SVR). Nevertheless, the majority of patients globally are unable to access these treatments because of cost and infrastructure constraints and, thus, remain untreated and uncured.
DATA SOURCE: Relevant articles of peginterferon (PegIFN)-based treatments in HCV and sofosbuvir-based treatments, simeprevir, daclatasvir/asunaprevir, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir, and grazoprevir/elbasvir, were searched in PubMed database, including general population and special population.
RESULTS: PegIFN in combination with ribavirin remains an important and relevant option for some patients, achieving SVR rates of up to 79% in genotype 1 and 89% in genotype 2 or 3 infections, which increases for patients with favorable IL28B genotypes. Triple therapy of DAA plus PegIFN/ribavirin is effective in treating difficult-to-cure patients infected with HCV genotype 3 or with resistance-associated variants. Owing to its long history in HCV management, the efficacy, tolerability and long-term outcomes associated with PegIFN alfa-2a are well established and have been validated in large-scale studies and in clinical practice for many populations. Furthermore, emerging data show that IFN-induced SVR is associated with lower incidences of hepatocellular carcinoma compared with DAAs. On the contrary, novel DAAs have yet to be studied in special populations, and long-term outcomes, particularly tumor development and recurrence in patients with cirrhosis and/or hepatocellular carcinoma, and reactivation of HBV in dually infected patients, are still unclear.
CONCLUSION: In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients.
|
|
|
|
|
| Fund: |
|
|
|
|
|
|
2017, Vol. 16 
